First China, then the world: new MEK blocker wins melanoma nod
Source: The Pharma Letter, March 2024
Shanghai-based KeChow Pharma has secured approval in its home country for tunlametinib, a MEK blocker which was discovered and developed by the firm in-house.
The oral therapy is approved for certain people with NRAS mutated melanoma who have already been treated with a checkpoint blocker.
A milestone approval for the company, the first since it was founded in 2014, the decision makes tunlametinib the first approved targeted therapy for this patient…